Galectin Therapeutics, Inc. announced that Harold H. Shlevin, currently the company's Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO) and President to succeed Peter G. Traber, who has tendered his resignation as President, CEO and Chief Medical Officer. The transition will be effective July 6, 2018. Harold has significant business development experience as an executive and will be responsible for directing and overseeing the potential partnering of NASH Phase 3 compound.

Dr. Shlevin will also oversee future NASH cirrhosis trials and is responsible for the company's clinical trials in cancer immunotherapy and any other potential new clinical trials in other indications. Dr. Shlevin is a 25-year bioscience-industry executive with broad senior management experience in development and commercialization of medical devices, pharmaceuticals, diagnostics and vaccines. Prior to his work at Galectin, Dr. Shlevin served Georgia Institute of Technology's Advanced Technology Development Center (ATDC) as manager of bioscience partnering and commercialization efforts.

He was also previously President and CEO of Solvay Pharmaceuticals US and a member of Solvay's global pharmaceutical management team.